Amgen India investment totals $200 million through 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Observations are largely around improvement of procedures and practices
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
The inspection was successfully completed
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Subscribe To Our Newsletter & Stay Updated